Baxter International - BAX Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 1 sell rating, 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BAX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BAX, but not buy additional shares or sell existing shares.
View BAX analyst ratings or view top-rated stocks.

12 Wall Street analysts have issued 12-month target prices for Baxter International's shares. Their BAX share price forecasts range from $43.00 to $75.00. On average, they expect the company's stock price to reach $55.14 in the next year. This suggests a possible upside of 37.7% from the stock's current price.
View analysts price targets for BAX or view top-rated stocks among Wall Street analysts.

Baxter International's stock was trading at $50.97 at the start of the year. Since then, BAX shares have decreased by 21.4% and is now trading at $40.06.
View the best growth stocks for 2023 here.

Baxter International saw a increase in short interest in February. As of February 28th, there was short interest totaling 4,170,000 shares, an increase of 12.7% from the February 13th total of 3,700,000 shares. Based on an average daily trading volume, of 6,030,000 shares, the short-interest ratio is currently 0.7 days.
View Baxter International's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our BAX earnings forecast.

Baxter International Inc. (NYSE:BAX) posted its quarterly earnings data on Thursday, February, 9th. The medical instruments supplier reported $0.88 earnings per share for the quarter, missing the consensus estimate of $0.94 by $0.06. The medical instruments supplier earned $3.89 billion during the quarter, compared to analyst estimates of $3.77 billion. Baxter International had a positive trailing twelve-month return on equity of 24.03% and a negative net margin of 16.10%. Baxter International's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the business earned $1.04 EPS.
Read the conference call transcript.

Baxter International declared a quarterly dividend on Tuesday, February 14th. Shareholders of record on Friday, February 24th will be given a dividend of $0.29 per share on Monday, April 3rd. This represents a $1.16 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date of this dividend is Thursday, February 23rd.
Read our dividend analysis for BAX.

ETFs with the largest weight of Baxter International (NYSE:BAX) stock in their portfolio include Simplify Health Care ETF (PINK), iShares U.S. Medical Devices ETF (IHI), Gabelli Love Our Planet & People ETF (LOPP), First Trust Indxx Medical Devices ETF (MDEV), Invesco S&P 500 Equal Weight Health Care ETF (RYH), SPDR S&P Health Care Equipment ETF (XHE), iShares MSCI Global Sustainable Development Goals ETF (SDG) and US Equity Dividend Select ETF (RNDV).

Baxter International (NYSE:BAX) pays an annual dividend of $1.16 per share and currently has a dividend yield of 3.09%.
Read our dividend analysis for BAX.

Baxter International issued an update on its first quarter 2023 earnings guidance on Thursday, February, 9th. The company provided EPS guidance of $0.46-$0.50 for the period, compared to the consensus EPS estimate of $0.76. The company issued revenue guidance of $3.60 billion-$3.60 billion, compared to the consensus revenue estimate of $3.61 billion.

506 employees have rated Baxter International Chief Executive Officer José (Joe) Almeida on Glassdoor.com. José (Joe) Almeida has an approval rating of 85% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Pfizer (PFE), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Abbott Laboratories (ABT), Procter & Gamble (PG), AT&T (T) and Verizon Communications (VZ).

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

Baxter International's stock is owned by a number of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.75%), Amundi (0.78%), California Public Employees Retirement System (0.67%), Cooke & Bieler LP (0.50%), Coho Partners Ltd. (0.39%) and Cincinnati Financial Corp (0.32%). Insiders that own company stock include Albert P L Stroucken, Andrew Frye, Brian Stevens, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth and Sean Martin.
View institutional ownership trends.

Shares of BAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BAX stock can currently be purchased for approximately $40.06.

Baxter International (NYSE:BAX) has a market capitalization of $20.22 billion and generates $15.11 billion in revenue each year. The medical instruments supplier earns $-2,433,000,000.00 in net income (profit) each year or ($4.83) on an earnings per share basis.

The company employs 60,000 workers across the globe.

Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The official website for the company is www.baxter.com. The medical instruments supplier can be reached via phone at (224) 948-2000, via email at global_corp_investor_relations@baxter.com, or via fax at 224-948-1813.